An extremely promising project in NMR analysis is helping deliver efficient, reliable screening of inborn errors in newborn health. It has the potential to generate a push-button, high throughput screening solution offering simultaneous non-targeted and targeted analysis.
Bruker’s participation in projects in Germany (Greifswald University Hospitals) and Turkey (12 hospitals coordinated by Infai GmbH) is helping to establish the screening method. Newborn health status in terms of growth, maturity, common disease recognition, and relativity to parameters not directly visible by NMR and more will be predicted using various statistical models that will have been developed beyond the extensively validated reference models.
In addition, a targeted approach using statistical methods, can quantify and reliably identify a substantial set of compounds.